Beijing Hotgen Biotech Co., Ltd. (SHA:688068)

Market Cap	11.74B +94.7%
Revenue (ttm)	407.69M -20.2%
Net Income	-210.52M
EPS	-2.24
Shares Out	88.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,352,064
Average Volume	1,886,861
Open	109.08
Previous Close	110.11
Day's Range	107.57 - 132.13
52-Week Range	80.59 - 262.22
Beta	1.47
RSI	53.83
Earnings Date	Apr 25, 2026

About Beijing Hotgen Biotech

Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, including upconversion light, chemiluminescence, sugar capture, microfluidics, and genetic testing for testing of intestinal microorganisms, gastrointestina...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 850
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688068

Financial Performance

In 2025, Beijing Hotgen Biotech's revenue was 407.69 million, a decrease of -20.20% compared to the previous year's 510.90 million. Losses were -210.52 million, 10.2% more than in 2024.